<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2023-12-2-21-33</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1479</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПОИСК И РАЗРАБОТКА НОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RESEARCH AND DEVELOPMENT OF NEW DRUG PRODUCTS</subject></subj-group></article-categories><title-group><article-title>Биоактивные производные ксантоновых С-гликозидов – QSAR-подход</article-title><trans-title-group xml:lang="en"><trans-title>Bioactive Xanthone C-glycoside Derivatives – QSAR Approach</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7661-1877</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аксенова</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Aksenova</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117198, г. Москва, ул. Миклухо-Маклая, д. 6</p></bio><bio xml:lang="en"><p>6, Mikluho-Maklaya str., Moscow, 117198</p></bio><email xlink:type="simple">aksenovav001@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1586-2183</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Морозова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Morozova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117198, г. Москва, ул. Миклухо-Маклая, д. 6</p></bio><bio xml:lang="en"><p>6, Mikluho-Maklaya str., Moscow, 117198</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3279-7520</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сыроешкин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Syroeshkin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117198, г. Москва, ул. Миклухо-Маклая, д. 6</p></bio><bio xml:lang="en"><p>6, Mikluho-Maklaya str., Moscow, 117198</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский университет дружбы народов» (РУДН)</institution></aff><aff xml:lang="en"><institution>Peoples Friendship University of Russia (RUDN University)</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>27</day><month>05</month><year>2023</year></pub-date><volume>12</volume><issue>2</issue><fpage>21</fpage><lpage>33</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Аксенова В.Н., Морозова М.А., Сыроешкин А.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Аксенова В.Н., Морозова М.А., Сыроешкин А.В.</copyright-holder><copyright-holder xml:lang="en">Aksenova V.N., Morozova M.A., Syroeshkin A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1479">https://www.pharmjournal.ru/jour/article/view/1479</self-uri><abstract><sec><title>Введение</title><p>Введение. Ксантоновые гликозиды обладают уникальной структурой и свойствами. Большое количество исследований направлено на поиск производных С-гликозида мангиферина с более высокой биодоступностью. Применение QSAR-анализа позволит оптимизировать направление поиска новых ксантоновых производных с заданными характеристиками.</p></sec><sec><title>Цель</title><p>Цель. Используя доступные дескрипторы химической структуры, физико-химических свойств и биоактивности молекул, проанализировать выборку известных гомологов и аналогов мангиферина с целью QSAR прогнозирования биологического действия новых ксантоновых С-гликозидов.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Объектами исследования служили 26 молекул природных гомологов и модифицированных производных мангиферина. С использованием программы ChemicPen построены топологические графы соединений. Для расчета топологического индекса Балабана, обладающего высокой дискриминирующей способностью, применили ПО ChemicDescript. Липофильность молекул (log P), а также критерии правила Липински, рассчитаны в Molinspiration. При помощи Pass Online прогнозирован спектр наиболее вероятной (Pa &gt; 0,7) биологической активности описываемых соединений. Для графического представления полученных результатов использовали ПО Origin (OriginLab, США).</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Мангиферин и его природные гомологи – наиболее гидрофильные соединения. Гидролиз С-гликозидной связи, алкилирование, ацилирование, введение аминозамещенного радикала в структуру мангиферина приводит к росту липофильных свойств. Спектр наиболее вероятной биологической активности описываемых молекул: противоопухолевое, антиоксидантное и кардиопротективное действие. Результаты ADMET моделирования на основе критериев подобия вещества лекарственному показали, что только 4 соединения соответствуют эмпирическому правилу пяти. Ошибка прогноза, установленная в результате кросс-валидации модели, связывающая индекс Балабана и липофильность соединений с их биоактивностью, составила в среднем не более 3 %.</p></sec><sec><title>Заключение</title><p>Заключение. Продемонстрирована взаимосвязь между структурой и свойствами обсуждаемых молекул. Открываются возможности прогнозирования свойств природных и синтетических ксантоновых С-гликозидов и дальнейшего использования полученных результатов для направленного синтеза новых соединений.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Xanthone glycosides have unique structures and properties. Many efforts focus on the search for C-glycoside derivatives of mangiferin with higher bioavailability. The application of the QSAR approach allows for the optimization of the search for novel xanthone derivatives with the desired characteristics.</p></sec><sec><title>Aim</title><p>Aim. Using available descriptors of chemical structure, physical-chemical properties, and biological activity, analyze a sample set of known homologs and analogs of mangiferin to QSAR prognosis bioactivity of new xanthone C-glycosides.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. 26 molecules of natural homologs and modified derivatives of mangiferin formed the analyzed sample set. Topological graphs of compounds were constructed using ChemicPen software. ChemicDescript software was used for the calculation of molecular descriptors, including the Balaban index. Physicochemical characteristics of molecules as well as Lipinski's rule criteria were calculated in Molinspiration. The spectrum of the most probable (Pa &gt; 0.7) biological activity of the described compounds were predicted using Pass Online. The software Origin (OriginLab, USA) was used for the graphical representation of the results.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Mangiferin and its natural homologs are the most hydrophilic compounds. The hydrolysis of the C-glycosidic bond, alkylation, acylation, and the introduction of an amino substituent radical into the mangiferin structure led to the increase of its lipophilic properties. The spectrum of the most probable biological activities of the described molecules: antitumor, antioxidant, and cardioprotective effects. The results of ADMET modeling based on the substance-drug similarity criteria showed that only 4 compounds correspond to the rule of five. We proposed the validation model to predict bioactivity from lipophilicity and molecule structure described with Balaban index. The error of prediction obtained in a result of cross-validation turned out to be about less than 3 %.</p></sec><sec><title>Conclusion</title><p>Conclusion. A correlation between the structure and properties of the molecules discussed has been demonstrated. The obtained results can be used for further prediction of the properties of natural and synthetic xanthone C-glycosides and directed synthesis of new active compounds.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>мангиферин</kwd><kwd>QSAR</kwd><kwd>хемоинформатика</kwd><kwd>ксантоновые С-гликозиды</kwd></kwd-group><kwd-group xml:lang="en"><kwd>mangiferin</kwd><kwd>QSAR</kwd><kwd>chemoinformatics</kwd><kwd>xanthone C-glycosides</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Публикация выполнена при поддержке Программы стратегического академического лидерства РУДН.</funding-statement><funding-statement xml:lang="en">The publication was carried out with the support by the PFUR’s Strategic Academic Leadership Program.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ishaque M., Bibi Y., Masood S., Al Ayoubi S., Qayyum A., Nisa S., Ahmed W. Xanthone C-glycosides isomers purified from Dryopteris ramosa (Hope) C. Chr. with bactericidal and cytotoxic prospects. Saudi J Biol Sci. 2022;29(2):1191–1196. DOI: 10.1016/j.sjbs.2021.09.047.</mixed-citation><mixed-citation xml:lang="en">Ishaque M., Bibi Y., Masood S., Al Ayoubi S., Qayyum A., Nisa S., Ahmed W. Xanthone C-glycosides isomers purified from Dryopteris ramosa (Hope) C. Chr. with bactericidal and cytotoxic prospects. Saudi J Biol Sci. 2022;29(2):1191–1196. DOI: 10.1016/j.sjbs.2021.09.047.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Q., Wang Y., Wu H., Yuan M., Zheng C., Xu H. Xanthone Glucosides: Isolation, Bioactivity and Synthesis. Molecules. 2021;26(18):5575. DOI: 10.3390/molecules26185575.</mixed-citation><mixed-citation xml:lang="en">Huang Q., Wang Y., Wu H., Yuan M., Zheng C., Xu H. Xanthone Glucosides: Isolation, Bioactivity and Synthesis. Molecules. 2021;26(18):5575. DOI: 10.3390/molecules26185575.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rubleva O. V. To the question of therapy and prevention of viral diseases. RMZH. 2012;11:571. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Rubleva O. V. To the question of therapy and prevention of viral diseases. RMZH. 2012;11:571. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lum P. T., Sekar M., Gan S. H., Jeyabalan S., Bonam S. R., Rani N. N. I. M., Ku-Mahdzir K. M., Seow L. J., Wu Y. S., Subramaniyan V., Fuloria N. K., Fuloria S. Therapeutic potential of mangiferin against kidney disorders and its mechanism of action: A review. Saudi J Biol Sci. 2022 Mar;29(3):1530–1542. DOI: 10.1016/j.sjbs.2021.11.016.</mixed-citation><mixed-citation xml:lang="en">Lum P. T., Sekar M., Gan S. H., Jeyabalan S., Bonam S. R., Rani N. N. I. M., Ku-Mahdzir K. M., Seow L. J., Wu Y. S., Subramaniyan V., Fuloria N. K., Fuloria S. Therapeutic potential of mangiferin against kidney disorders and its mechanism of action: A review. Saudi J Biol Sci. 2022 Mar;29(3):1530–1542. DOI: 10.1016/j.sjbs.2021.11.016.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mittal S., Iqubal M. K., Iqbal B., Gupta M. M., Ali J., Baboota S. A pervasive scientific overview on mangiferin in the prevention and treatment of various diseases with preclinical and clinical updates. Journal of Complementary and Integrative Medicine. 2021;18(1):9–21. DOI: 10.1515/jcim-2019-0250.</mixed-citation><mixed-citation xml:lang="en">Mittal S., Iqubal M. K., Iqbal B., Gupta M. M., Ali J., Baboota S. A pervasive scientific overview on mangiferin in the prevention and treatment of various diseases with preclinical and clinical updates. Journal of Complementary and Integrative Medicine. 2021;18(1):9–21. DOI: 10.1515/jcim-2019-0250.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Jyotshna, Khare P., Shanker K. Mangiferin: A review of sources and interventions for biological activities. BioFactors. 2016;42(5):504–514. DOI: 10.1002/biof.1308.</mixed-citation><mixed-citation xml:lang="en">Jyotshna, Khare P., Shanker K. Mangiferin: A review of sources and interventions for biological activities. BioFactors. 2016;42(5):504–514. DOI: 10.1002/biof.1308.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Telang M., Dhulap S., Mandhare A., Hirwani R. Therapeutic and cosmetic applications of mangiferin: a patent review. Expert Opin Ther Pat. 2013;23(12):1561–1580. DOI: 10.1517/13543776.2013.836182.</mixed-citation><mixed-citation xml:lang="en">Telang M., Dhulap S., Mandhare A., Hirwani R. Therapeutic and cosmetic applications of mangiferin: a patent review. Expert Opin Ther Pat. 2013;23(12):1561–1580. DOI: 10.1517/13543776.2013.836182.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ehianeta T. S., Laval S., Yu B. Bio- and chemical syntheses of mangiferin and congeners. BioFactors. 2016;42(5):445–458. DOI: 10.1002/biof.1279.</mixed-citation><mixed-citation xml:lang="en">Ehianeta T. S., Laval S., Yu B. Bio- and chemical syntheses of mangiferin and congeners. BioFactors. 2016;42(5):445–458. DOI: 10.1002/biof.1279.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S. K., Sinha S. K., Prasad S. K., Kumar R., Bithu B. S., Kumar S. S., Singh P. Synthesis and evaluation of novel analogues of mangiferin as potent antipyretic. Asian Pac J Trop Med. 2011;4(11):866–869. DOI: 10.1016/S1995-7645(11)60210-1.</mixed-citation><mixed-citation xml:lang="en">Singh S. K., Sinha S. K., Prasad S. K., Kumar R., Bithu B. S., Kumar S. S., Singh P. Synthesis and evaluation of novel analogues of mangiferin as potent antipyretic. Asian Pac J Trop Med. 2011;4(11):866–869. DOI: 10.1016/S1995-7645(11)60210-1.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S. K., Kumar Y., Kumar S., Sharma V. K., Dua K., Samad A. Antimicrobial evaluation of mangiferin and its synthesized analogues. Indian J Pharm Sci. 2009;71(3):328–331. DOI: 10.4103/0250-474X.56023.</mixed-citation><mixed-citation xml:lang="en">Singh S. K., Kumar Y., Kumar S., Sharma V. K., Dua K., Samad A. Antimicrobial evaluation of mangiferin and its synthesized analogues. Indian J Pharm Sci. 2009;71(3):328–331. DOI: 10.4103/0250-474X.56023.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Popov V. I. ChemicPen. Certificate of official registration of a software № 2005612073. Rospatent. 2005.</mixed-citation><mixed-citation xml:lang="en">Popov V. I. ChemicPen. Certificate of official registration of a software № 2005612073. Rospatent. 2005.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Miličević A., Šinko G. Use of connectivity index and simple topological parameters for estimating the inhibition potency of acetylcholinesterase. Saudi Pharm J. 2022;30(4):369–376. DOI: 10.1016/j.jsps.2022.01.025.</mixed-citation><mixed-citation xml:lang="en">Miličević A., Šinko G. Use of connectivity index and simple topological parameters for estimating the inhibition potency of acetylcholinesterase. Saudi Pharm J. 2022;30(4):369–376. DOI: 10.1016/j.jsps.2022.01.025.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Marukhlenko A. V., Morozova, M. A., Mbarga, A. M. J., Antipova N. V., Syroeshkin A. V., Podoprigora, I. V., Maksimova T. V. Chelation of Zinc with Biogenic Amino Acids: Description of Properties Using Balaban Index, Assessment of Biological Activity on Spirostomum Ambiguum Cellular Biosensor, Influence on Biofilms and Direct Antibacterial Action. Pharmaceuticals. 2022;15:979. DOI: 10.3390/ph15080979.</mixed-citation><mixed-citation xml:lang="en">Marukhlenko A. V., Morozova, M. A., Mbarga, A. M. J., Antipova N. V., Syroeshkin A. V., Podoprigora, I. V., Maksimova T. V. Chelation of Zinc with Biogenic Amino Acids: Description of Properties Using Balaban Index, Assessment of Biological Activity on Spirostomum Ambiguum Cellular Biosensor, Influence on Biofilms and Direct Antibacterial Action. Pharmaceuticals. 2022;15:979. DOI: 10.3390/ph15080979.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Popov V. I. ChemicDescript. Certificate of official registration of a software № 2003612305. Rospatent. 2003.</mixed-citation><mixed-citation xml:lang="en">Popov V. I. ChemicDescript. Certificate of official registration of a software № 2003612305. Rospatent. 2003.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hadda T. B., Rastija V., AlMalki F., Titi A., Touzani R., Mabkhot Y. N., Khalid S., Zarrouk A., Siddiqui B. S. Petra/Osiris/Molinspiration and molecular docking analyses of 3-hydroxy-indolin-2-one derivatives as potential antiviral agents. Current Computer-Aided Drug Design. 2021;17(1):123–133. DOI: 10.2174/1573409916666191226110029.</mixed-citation><mixed-citation xml:lang="en">Hadda T. B., Rastija V., AlMalki F., Titi A., Touzani R., Mabkhot Y. N., Khalid S., Zarrouk A., Siddiqui B. S. Petra/Osiris/Molinspiration and molecular docking analyses of 3-hydroxy-indolin-2-one derivatives as potential antiviral agents. Current Computer-Aided Drug Design. 2021;17(1):123–133. DOI: 10.2174/1573409916666191226110029.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yao H., Xie Q., He Q., Zeng L., Long J., Gong Y., Li X., Li X., Liu W., Xu Z., Wu H., Zheng C., Gao Y. Pretreatment with Panaxatriol Saponin Attenuates Mitochondrial Apoptosis and Oxidative Stress to Facilitate Treatment of Myocardial Ischemia-Reperfusion Injury via the Regulation of Keap1/Nrf2 Activity. Oxidative Medicine and Cellular Longevity. 2022;2022:9626703. DOI: 10.1155/2022/9626703.</mixed-citation><mixed-citation xml:lang="en">Yao H., Xie Q., He Q., Zeng L., Long J., Gong Y., Li X., Li X., Liu W., Xu Z., Wu H., Zheng C., Gao Y. Pretreatment with Panaxatriol Saponin Attenuates Mitochondrial Apoptosis and Oxidative Stress to Facilitate Treatment of Myocardial Ischemia-Reperfusion Injury via the Regulation of Keap1/Nrf2 Activity. Oxidative Medicine and Cellular Longevity. 2022;2022:9626703. DOI: 10.1155/2022/9626703.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Carmichael N., Day P. J. R. Cell Surface Transporters and Novel Drug Developments. Front Pharmacol. 2022;13:852938. DOI: 10.3389/fphar.2022.852938.</mixed-citation><mixed-citation xml:lang="en">Carmichael N., Day P. J. R. Cell Surface Transporters and Novel Drug Developments. Front Pharmacol. 2022;13:852938. DOI: 10.3389/fphar.2022.852938.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Madkhali O. A. Perspectives and Prospective on Solid Lipid Nanoparticles as Drug Delivery Systems. Molecules. 2022;27(5):1543. DOI: 10.3390/molecules27051543.</mixed-citation><mixed-citation xml:lang="en">Madkhali O. A. Perspectives and Prospective on Solid Lipid Nanoparticles as Drug Delivery Systems. Molecules. 2022;27(5):1543. DOI: 10.3390/molecules27051543.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hamdy N. M., Eskander G., Basalious E. B. Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques. Int J Nanomedicine. 2022;17:6131–6155. DOI: 10.2147/IJN.S386037.</mixed-citation><mixed-citation xml:lang="en">Hamdy N. M., Eskander G., Basalious E. B. Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques. Int J Nanomedicine. 2022;17:6131–6155. DOI: 10.2147/IJN.S386037.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Morozova M. A., Tumasov V. N., Kazimova I. V., Maksimova T. V., Uspenskaya E. V., Syroeshkin A. V. Second-order scattering quenching in fluorescence spectra of natural humates as a tracer of formation stable supramolecular system for the delivery of poorly soluble antiviral drugs on the example of mangiferin and favipiravir. Pharmaceutics. 2022;14(4):767. DOI: 10.3390/pharmaceutics14040767.</mixed-citation><mixed-citation xml:lang="en">Morozova M. A., Tumasov V. N., Kazimova I. V., Maksimova T. V., Uspenskaya E. V., Syroeshkin A. V. Second-order scattering quenching in fluorescence spectra of natural humates as a tracer of formation stable supramolecular system for the delivery of poorly soluble antiviral drugs on the example of mangiferin and favipiravir. Pharmaceutics. 2022;14(4):767. DOI: 10.3390/pharmaceutics14040767.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
